Description
Release form
Ointment for external use.
10 g
packaging
Pharmacological action of
corticosteroids. Suppresses the function of white blood cells and tissue macrophages. It limits the migration of leukocytes to the area of inflammation. It violates the ability of macrophages to phagocytosis, as well as to the formation of interleukin-1. Helps stabilize lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the area of inflammation. Reduces capillary permeability due to histamine release. Suppresses fibroblast activity and collagen formation.
Inhibits the activity of phospholipase A2, which inhibits the synthesis of prostaglandins and leukotrienes. It inhibits the release of COX (mainly COX-2), which also helps to reduce the production of prostaglandins.
Reduces the number of circulating lymphocytes (T and B cells), monocytes, eosinophils and basophils due to their movement from the vascular bed to the lymphoid tissue inhibits the formation of antibodies.
Suppresses the release by the pituitary gland of ACTH and -lipotropin, but does not reduce the level of circulating -endorphin. It inhibits the secretion of TSH and FSH.
With direct application to the vessels, it has a vasoconstrictor effect.
Has a pronounced dose-dependent effect on the metabolism of carbohydrates, proteins and fats. It stimulates gluconeogenesis, promotes the uptake of amino acids by the liver and kidneys and increases the activity of gluconeogenesis enzymes. In the liver, it enhances the deposition of glycogen, stimulating the activity of glycogen synthetase and the synthesis of glucose from protein metabolism products. An increase in blood glucose activates the release of insulin.
Suppresses the uptake of glucose by fat cells, leading to the activation of lipolysis. However, due to an increase in insulin secretion, lipogenesis is stimulated, which contributes to the accumulation of fat.
It has a catabolic effect in lymphoid and connective tissue, muscles, adipose tissue, skin, and bone tissue.
Osteoporosis and Itsenko-Cushing’s syndrome are the main factors limiting the long-term therapy of corticosteroids. As a result of catabolic action, growth inhibition in children is possible.
In high doses, it can increase the excitability of brain tissue and helps lower the threshold for convulsive readiness. Stimulates excess production of hydrochloric acid and pepsin in the stomach, which contributes to the development of peptic ulcers.
In systemic use, therapeutic activity is due to anti-inflammatory, anti-allergic, immunosuppressive and antiproliferative effects.
When applied topically and locally, the therapeutic activity of triamcinolone acetonide is due to the anti-inflammatory, anti-allergic and antiexudative (due to vasoconstrictor effect) effect.
The anti-inflammatory activity of triamcinolone acetonide is 6 times more active than hydrocortisone. The mineralocorticoid activity of triamcinolone acetonide is practically absent.
Indications
For systemic use: asthma, chronic bronchitis with bronchial obstructive syndrome, pemphigoid, psoriasis, dermatitis.
Intra-articular administration: chronic inflammatory joint diseases, exudative arthritis, gout, dropsy of the joints, blockage of the shoulder joint, chronic inflammation of the inner layer of the joint capsule.
For external use: eczema, psoriasis, neurodermatitis, various types of dermatitis and other inflammatory and allergic skin diseases of non-microbial etiology (as part of complex therapy).
Contraindications
History of acute psychosis, active tuberculosis, myasthenia gravis, neoplasms with metastases, diverticulitis, gastric ulcer and duodenal ulcer, arterial hypertension, Itsenko-Cushing’s syndrome, renal disease, renal disease hidden foci of infection, amyloidosis, syphilis, fungal diseases, viral infections (including those caused by Herpes simplex and Varicella zoster), amoebic infections, polio (except for bulbar-encephalitis form), gonococcal or tuberculous arthritis, vaccination period, lymphadenitis after BCG vaccination, glaucoma, infected skin lesions.
Special instructions
Not intended for iv administration.
Used with caution and under strict medical supervision in case of edematous syndrome, obesity, mental illness and gastrointestinal diseases. During treatment, it is recommended to take vitamin D and consume foods rich in calcium.
When applied topically to prevent local infectious complications, it is recommended to use in combination with antimicrobial agents.
Parenteral use in childrenup to 6 years of age is not recommended at the age of 6-12 years – according to strict indications.
Avoid prolonged external use in children, regardless of age.
Composition
Active ingredient: triamcinolone acetonide 0.1 g
Excipients: glycerin, propylene glycol, dimexide, petrolatum, stearic acid, emulsifying wax, purified water.
Dosage and administration
Triacort ointment is applied evenly with a thin layer to the affected skin areas 1-3 times a day. The duration of treatment depends on the nature of the disease and the effectiveness of therapy, usually amounting to 5-10 days. With a persistent course of the disease, the course of treatment can be extended up to 25 days. On limited lesions, Triacort Ointment can be used under an occlusive dressing to enhance the effect.
Treatment begins with 0.1% ointment, when the therapeutic effect is achieved, they go to 0, 025% ointment with its gradual cancellation.
This tactic provides a more lasting effect and reduces the risk of an aggravation of the process after drug withdrawal.
Side effects of
From the endocrine system: redistribution of adipose tissue, menstrual irregularities, increased blood glucose, inhibition of adrenal function, moon face, striae, hirsutism, acne.
Metabolism: edema, electrolyte imbalance, negative nitrogen balance, growth retardation in children.
From the digestive system: steroid gastric ulcer, erosive and ulcerative lesions of the gastrointestinal tract, acute pancreatitis.
From the side of the central nervous system: cramps, sleep disturbances, mental disorders, headaches and dizziness, weakness.
From the musculoskeletal system: myopathy, osteoporosis.
From the cardiovascular system: arterial hypertension.
From the blood coagulation system: thromboembolism.
From the side of the organ of vision: visual impairment, posterior subcapsular cataract, increased intraocular pressure or exophthalmos, anaphylactic reactions.
Reactions due to immunosuppressive effects: exacerbation of infectious diseases.
With intra-articular administration: joint pain, irritation at the injection site, depigmentation, sterile abscess are possible, skin atrophy, when administered in doses of more than 40 mg, resorptive side effects are possible.
For external use: itching, skin irritation, late reactions such as eczema, steroid acne, purpura are possible. With prolonged use of the ointment, the development of secondary infectious lesions and atrophic changes in the skin is possible.
Drug Interactions
With simultaneous use with anabolic steroids, androgens, the risk of developing peripheral edema and acne is increased.
With simultaneous use with antithyroid drugs and thyroid hormones, a change in thyroid function is possible.
With simultaneous use with histamine H1 receptor blockers, the effect of triamcinolone with hormonal contraceptives decreases – the effect of triamcinolone is potentiated.
Hypocalcemia associated with the use of triamcinolone can lead to an increase in the duration of neuromuscular blockade caused by the action of depolarizing muscle relaxants when used simultaneously.
When used simultaneously with immunosuppressants, the risk of developing bacterial and viral infections is increased.
With simultaneous use with potassium-sparing diuretics, hypokalemia is possible.
With simultaneous use, a decrease in the effectiveness of indirect anticoagulants, heparin, streptokinases, urokinases, increased risk of erosive and ulcerative lesions and bleeding from the digestive tract.
When used concomitantly with NSAIDs (including acetylsalicylic acid), the risk of erosive-ulcerative lesions and bleeding from the gastrointestinal tract increases.
With simultaneous use, the action of oral hypoglycemic agents, insulin with laxatives is weakened – hypokalemia with cardiac glycosides is possible – the risk of developing heart rhythm disturbances and other toxic effects of glycosides is increased.
With simultaneous use with tricyclic antidepressants, it is possible to increase mental disorders associated with taking triamcinolone.
Storage conditions
At a temperature of 12 15 ° C.
Term hodnosty
2 years
Deystvuyuschee substances
triamcinolone
Dosage form
ointment
appointment of
Adult on prescription, Children on prescription
Indications
psoriasis, diathesis, dermatitis, insect bites, Allergy, Neurodermatitis, Dermatitis
Akrikhin HFO AO, Russia
